Table 2.
APPI Analysis | ESI Analysis | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sample | ASD | T | 5-ADiol | DHEA | 5α-ASD | DHT | AND | ASD | T | 5-ADiol | DHEA | 5α-ASD | DHT | AND |
CWR-R1 Cells, 24 h 0.1 uM 5-androstan-3α,17β-diol treatmentb | 0.150 | 0.836 | 1.05 | 0.225 | NA | 24.0 | 9.21 | 0.139 | 0.828 | ND | NQ | 5.745 | 23.7 | 7.26 |
CWR-R1 Cells, 48h 0.1 uM 5-androstan-3α,17β-diol treatmentb | 0.392 | 1.84 | 1.79 | 0.672 | NA | 5.90 | 4.80 | 0.359 | 1.78 | ND | NQ | 2.40 | 5.98 | 4.12 |
PC-3 Cells, 24 h 0.1 uM 5-androstan-3α,17β-diol treatmentb | 0.341 | 0.102 | ND | 0.284 | 12.0 | 5.76 | 58.5 | 0.314 | 0.095 | ND | NQ | 13.7 | 6.39 | 51.6 |
Androgen Stimulated Rat Prostate #1c | 0.22 | 0.48 | ND | 3.42 | ND | 1.24 | NQ | 0.32 | 0.48 | ND | ND | NQ | 2.04 | NQ |
Androgen Stimulated Rat Prostate #2c | 0.80 | 1.22 | ND | 4.36 | ND | 4.44 | NQ | 1.06 | 1.42 | ND | ND | NQ | 4.28 | NQ |
Recurrent CaP #1c | 0.18 | 0.06 | ND | 5.28 | ND | 0.58 | 1.02 | 0.24 | 0.04 | ND | ND | NQ | 0.70 | ND |
Recurrent CaP #2c | 0.26 | 0.52 | ND | 4.64 | ND | ND | 3.6 | 0.24 | 0.54 | ND | ND | NQ | 0.66 | ND |
Benign Human Prostate Peripheral Zone #1c | 1.18 | 0.60 | 40.8 | 224 | ND | 1.46 | NQ | ND | 0.18 | ND | ND | NQ | 61.2 | NQ |
Benign Human Prostate Peripheral Zone #2c | 1.42 | 0.72 | 93.4 | 204 | 21.2 | 1.8 | NQ | 2.32 | 0.36 | ND | NQ | ND | 128 | NQ |
Benign Human Prostate Transition Zone #1c | 2.72 | 1.48 | ND | 78.1 | ND | 9.74 | NQ | 1.12 | 5.44 | ND | ND | ND | 115 | NQ |
Benign Human Prostate Transition Zone #2c | 0.46 | 0.52 | ND | 15.1 | ND | 1.6 | NQ | 0.16 | 0.46 | ND | NQ | ND | 110 | NQ |
NA = not analyzed; ND = not detected; NQ = S:N < 3 or ratio of quantifying ion to confirmatory ion out of accepted range
ng/mL media
ng/g tissue